- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Breast MR beats mammo, ultrasound for women with nipple discharge
In women with nipple discharge, contrast breast MR has higheroverall sensitivity for detecting malignant and high-risk lesionsthan mammography or ultrasound.
In women with nipple discharge, contrast breast MR has higher overall sensitivity for detecting malignant and high-risk lesions than mammography or ultrasound.
Between March 2007 and July 2009, 38 women with nipple discharge underwent ultrasound, mammography, and contrast MR (1.5T). A malignant lesion was found in five of 38 patients. A high-risk lesion was found in 14 of 38 patients. Contrast MR found all five of the cancers and 13 of the 14 high-risk lesions for a sensitivity of 94.74%. Mammography had a sensitivity of 26.32%; ultrasound had a sensitivity of 63.16%.
Contrast MR should be recommended when conventional imaging is negative, according to Dr. Michele Lorenzon, from the radiology department at the University of Udine in Italy. The study was presented at the European Congress of Radiology in Vienna in March.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
